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Abstract
 
Regulation of survival, expansion, and differentiation of erythroid progenitors requires the
well-controlled activity of signaling pathways induced by erythropoietin (Epo) and stem cell
factor (SCF). In addition to qualitative regulation of signaling pathways, quantitative control
may be essential to control appropriate cell numbers in peripheral blood. We demonstrate that
Bruton’s tyrosine kinase (Btk) is able to associate with the Epo receptor (EpoR) and Jak2, and
is a substrate of Jak2. Deficiency of Btk results in reduced and delayed phosphorylation of the
EpoR, Jak2, and downstream signaling molecules such as Stat5 and PLC
 
 
 
1 as well as in decreased
responsiveness to Epo. As a result, expansion of erythroid progenitors lacking Btk is impaired at
limiting concentrations of Epo and SCF. In addition, we show that SCF induces Btk to interact
with TNF-related apoptosis-inducing ligand (TRAIL)–receptor 1 and that lack of Btk results
in increased sensitivity to TRAIL-induced apoptosis. Together, our results indicate that Btk is
a novel, quantitative regulator of Epo/SCF-dependent expansion and survival in erythropoiesis.
Key words: Jak2 • Stat5 • hematopoiesis • signal transduction
 
Introduction
 
Signals emanating from the receptors for erythropoietin
(Epo) receptor and stem cell factor (SCF) (c-Kit) are crucial
to positively regulate erythropoiesis. Epo or EpoR knockout
mice die at day 12.5 of embryonic development with a lack
of erythrocytes (1), whereas mice carrying mutations in c-Kit
or SCF are severely anemic (2). In vivo, physiological Epo
concentrations are suboptimal, causing apoptosis of 
 
 
 
20%
of the erythroid cells present in bone marrow (3). This
apoptotic process may be further enhanced upon activation
 
of “death receptors” (4) of which Fas and receptors
for TNF
 
 
 
 and TNF-related apoptosis-inducing ligand
(TRAIL) are expressed in erythroid progenitors (5–7). The
observed apoptosis is probably caused by interplay of apop-
totic and survival factors. For instance, in myelodysplastic
syndrome (MDS), the lack of erythrocytes has been attributed
to a failure to respond to Epo as well as by enhanced sensitivity
to death ligands (8, 9).
Ex vivo, erythroid progenitors can be expanded in the
presence of Epo, SCF, and glucocorticoids, whereas Epo
alone induces differentiation to erythrocytes (10–12). Acti-
vation of the EpoR and c-Kit results in phosphorylation of
the receptors and activation of multiple signaling pathways
(13–15). Common signaling pathways involve Src-like
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Btk, Bruton’s tyrosine kinase; Dex, dexa-
methasone; Epo, erythropoietin; MDS, myelodysplastic syndrome; PKC,
protein kinase C; RE, reexpressing; SCF, stem cell factor; TCL, total
cell  lysate; TRAIL, TNF-related apoptosis-inducing ligand; TRAILR1,
TRAIL receptor 1. 
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kinases, PI3 kinase, PLC
 
 
 
1 and ERK1/2, whereas Stat5
phosphorylation is only induced by Epo (for review see
references 16, 17). Although the molecular mechanisms of
Epo/SCF synergy in progenitor expansion are unknown, it
may involve the specific activation of cooperating down-
stream effector molecules, or changes in signaling strength
and/or duration. For instance, PI3 kinase activation of
PKB/Akt is significantly higher after SCF stimulation and
persists longer than Epo-induced PKB/Akt phosphoryla-
tion (reference 10 and unpublished data). Inhibition of PI3
kinase abrogates expansion of erythroid progenitors and in-
duces differentiation instead (10).
PI3 kinase activity generates phosphatidylinositol-3-phos-
phates (e.g., PIP
 
3
 
), which target proteins with a pleckstrin
homology domain to the plasma membrane. This includes
members of the Tec family of cytoplasmic tyrosine kinases
(i.e., Bmx/Etk, Bruton’s tyrosine kinase [Btk], Itk, and Tec;
reference 18). Tec kinases are primarily expressed in he-
matopoietic lineages (19). Btk represents the most exten-
sively studied member of the family. Btk mutations or defi-
ciency cause X-linked agammaglobulinemia, a block in B
cell development, in humans and the milder X-linked im-
munodeficiency phenotype in mice (20–22). Btk controls B
cell receptor signaling and sensitivity to apoptosis induction.
In DT40 cells, Btk associates with Fas and inhibits Fas-
induced apoptosis (23), whereas Btk is required in the same
cell type for radiation-induced apoptosis (24). Activation of
Tec family kinases is largely dependent on the synergistic ac-
tion of PI3 kinase and a Src-like kinase activity (25), al-
though alternative pathways have been suggested (26). The
PH-domain of Tec kinases imposes membrane recruitment
(27), which results in phosphorylation on a tyrosine residue
in the kinase domain (e.g., Y551 in Btk). The subsequent
conformational change releases intramolecular inhibitory in-
teractions, allows autophosphorylation within the SH3 do-
main (e.g., Y223 in Btk), and maximum kinase activity (28–
30). Tec, as well as Btk, was also shown to associate with the
non–Src-like kinases Syk, Jak1, and Jak2 in COS cells (31–
33). Tec and Jak2 were shown to cross-phosphorylate each
other (31, 32), but the physiological significance of this in-
teraction has not been investigated.
Expression of Btk and Tec in erythroid cells has been
described previously (34, 35), but so far only the role of
Tec in c-Kit signaling has been studied in more detail (36).
The analysis of erythroid progenitors derived from 
 
wt
 
 and
Btk-deficient (Btk
 
 
 
) mice showed that Btk is required for
progenitor expansion at low, physiological growth factor
concentrations. At the molecular level, Btk enhanced Jak2
activity and loss of Btk resulted in reduced Epo-induced
phosphorylation of EpoR, Jak2, Stat5a/b, and PLC
 
 
 
1. In
addition, Btk
 
 
 
 progenitors are highly sensitive to TRAIL-
induced apoptosis because they lack SCF-induced associa-
tion of Btk with TRAIL receptor 1 (TRAILR1).
 
Materials and Methods
 
Antibodies, Growth Factors, and Plasmids.
 
Rabbit antisera
against Jak2, a mouse monoclonal antibody recognizing phos-
 
pho-Stat5a/b (Tyr694-Stat5a and Tyr 699-Stat5b) and antibodies
for TRAILR1/2 were obtained from Upstate Biotechnology.
Rabbit antisera recognizing the mouse EpoR, PLC
 
 
 
1, Btk,
c-Kit, and the antiphosphotyrosine mouse monoclonal antibody
PY99 were obtained from Santa Cruz Biotechnology, Inc. Phos-
pho-Btk (Tyr223) was obtained from Cell Signaling. Anti-Actin
antibody was obtained from Sigma-Aldrich. Recombinant hu-
man Epo was a gift from Ortho-Biotech. Dexamethasone (Dex)
was purchased from Sigma-Aldrich; mouse SCF and recombinant
TRAIL was obtained from R&D Systems. The complete open
reading frame of Btk and Btk kinase dead (K430R, a gift from J.
Borst, Netherlands Cancer Institute, Amsterdam, Netherlands),
Tec, Jak2, Lyn, c-Kit, and EpoR was cloned into the mammalian
expression vector pSG5 (Stratagene). Additionally, Btk was
cloned into the retroviral vector pBabe-puro.
 
Cell Lines, Primary Erythroid Cultures, Transfections, and Viral
Transductions.
 
COS and ecotropic Phoenix (
 
 
 
E) cells were
maintained in DMEM supplemented with 10% FCS (Life Tech-
nologies). For COS transfection experiments, 10
 
6
 
 cells were
seeded in 60-mm dishes, transfected with 12 
 
 
 
g DNA for 3–4 h,
washed, and harvested after 48 h as described previously (36). Pri-
mary fetal liver and bone marrow erythroid progenitors as well as
erythroid bone marrow cell lines (see Online Supplemental Ma-
terial section; reference 37) were cultured in StemPro-34™ me-
dium (Life Technologies) supplemented with 2 U/ml Epo, 100
ng/ml SCF, and 1 
 
 
 
M Dex, unless indicated differently. Cell
cultures were maintained at 1.5–3 
 
 
 
 10
 
6
 
 cells/ml. To induce ter-
minal erythroid differentiation, cells were washed in PBS and re-
seeded at 2–3 
 
 
 
 10
 
6
 
 cells/ml in StemPro-34™ medium contain-
ing insulin (4 
 
 
 
 10
 
 
 
4
 
 IE/ml; Actrapid HM), the Dex antagonist
ZK-112993 (3 
 
 
 
 10
 
 
 
6
 
 M; reference 12), 1 mg/ml of iron-satu-
rated human transferrin (Sigma-Aldrich), and various concentra-
tions of Epo as indicated.
Viral transduction of the Btk
 
 
 
 erythroid bone marrow cell line
3G4 was performed as follows: 
 
 
 
E cells were transfected as de-
scribed for COS cells. After 48 h of transfection, cells were
treated with 10 
 
 
 
g/ml mitomycin C (Kyowa) for 1 h, washed 3
times with PBS, left untreated for 4 h, and washed; 3G4 cells
were added (0.5 
 
 
 
 10
 
6
 
 cells/transfection) to be cocultured in
StemPro-34™ medium supplemented with growth factors as
aforementioned. After 48 h, the erythroid cells were transferred
from the 
 
 
 
E cell layer to a new dish and selected for stable trans-
fectants with 2 
 
 
 
g/ml puromycine (Sigma-Aldrich). To obtain
single cell–derived clones, cells were seeded in semi-solid Stem-
Pro-34™ medium supplemented with Epo, SCF, and Dex plus
puromycin (2 
 
 
 
g/ml).
 
Immunoprecipitations and Western Blotting.
 
Primary erythroid
cells and the erythroid bone marrow cell lines were factor de-
prived in plain IMDM (Life Technologies) for 4 h at 5 
 
 
 
 10
 
6
 
 and
restimulated for 10 min at 37
 
 
 
C (40–80 
 
 
 
 10
 
6
 
/ml) with 500 ng/
ml SCF, 5 U/ml Epo, 200 ng/ml TRAIL, or combinations of
factors at concentrations indicated in the figure legends. To stop
the reaction, 10 volumes of ice-cold PBS were added. Cell lysis,
immunoprecipitation, SDS-PAGE, and Western blotting were
performed as described previously (36). Membranes were
stripped in 63 mM Tris-HCl, pH 6.1, 2% SDS, and 100 mM
 
 
 
-mercaptoethanol for 30 min at 50
 
 
 
C after which they were re-
blocked and restained.
 
Hemoglobin Content Determination and Cell Morphology.
 
Small
aliquots of the cultures were removed and analyzed for hemoglo-
bin content by photometry as described previously (38). The val-
ues described were the average of triplicate measurements after
normalization for cell number and mean single cell volume. For 
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histological analysis, erythroid cells at various stages of cell culture
were cytocentrifuged onto glass slides and subsequently stained
with histological dyes and neutral benzidine for hemoglobin as
described previously (39). Nucleated and enucleated erythrocytes
(brown or yellow stained, small cells), partially mature or imma-
ture cells (larger cells with gray or blue cytoplasm), and dead cells
(fragmented/condensed nuclei, disintegrated cells) were counted
under a microscope, evaluating 
 
 
 
600 cells on multiple, randomly
selected fields per sample (49, 51). Images were taken using a
CCD camera and were processed with Adobe Photoshop.
 
Membrane Expression of Various Receptors.
 
Flow cytometric
analysis was performed essentially as described previously (22).
Antibodies recognizing c-Kit, TER119, and Integrin
 
 
 
4 were ob-
tained from BD Biosciences. Biotinylated Epo was made using
the biotin labeling kit (cat. no. 1418165; Roche) following the
manufacturer’s protocol.
 
Online Supplemental Material. 
 
Online supplemental material
describes (a) how the bone marrow–derived cell lines used in
these studies were established, (b) peripheral blood parameters
and colony-forming progenitors present in the fetal liver of 
 
wt
 
and Btk-deficient mice (Table SI), and (c) the response of 
 
wt
 
 and
Btk-deficient mice to hypoxia (phenylhydrazine-induced stress
erythropoiesis in the spleen; Fig. S1). Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20031109/DC1.
 
Results
 
Btk Is Phosphorylated in Response to Epo and SCF.
 
To
address whether Btk has a functional role in Epo/SCF-
dependent erythropoiesis, we tested if Btk is tyrosine phos-
phorylated in response to Epo or SCF. Erythroid progen-
itors expanded from E12.5 mouse fetal liver were factor
deprived and restimulated with Epo and SCF. Epo as well
as SCF induced tyrosine phosphorylation of the Btk auto-
phosphorylation site Y223 with similar kinetics and inten-
sity, whereas costimulation with both Epo and SCF re-
sulted in a similar phosphorylation intensity of Btk (Fig. 1
A). Phosphorylation of Btk was also detected with the an-
tiphosphotyrosine antibody PY99 (unpublished data). Be-
cause activation of Btk in B cells is dependent on PI3 ki-
nase and Src-like kinases, we examined the presence of a
similar mechanism in erythroid cells. Immortalized ery-
throid progenitors were factor deprived and restimulated
in the presence of increasing inhibitor concentrations sup-
pressing PI3 kinase (LY294002 [LY]) or Src-like kinases
(PP2). Btk tyrosine phosphorylation was dose-depen-
dently inhibited by LY with complete inhibition at 30–45
 
 
 
M (Fig. 1 B). Inhibition of Src family kinases with PP2
(0.1–5 
 
 
 
M) did not result in an inhibition of Btk tyrosine
phosphorylation (Fig. 1 C, top rectangle, bottom band).
Inhibition of (unknown) tyrosine-phosphorylated pro-
teins in total cell lysates by PP2 indicated that the inhibi-
tor was functional. Unfortunately, the Src kinase inhibi-
tors cannot be used to examine whether SCF-induced
Btk phosphorylation is dependent on Src kinases because
they directly inhibit c-Kit kinase activity (reference 40
and unpublished data). In conclusion, Epo induces PI3 ki-
nase–dependent and Src kinase–independent activation of
Btk in erythroid progenitors.
 
Btk Interacts with the EpoR and Jak2 and Is Tyrosine Phos-
phorylated by Jak2.
 
The Epo-dependent activation of Btk
suggests that Btk may interact with the EpoR and/or Jak2.
Btk was expressed in COS cells together with Jak2 and/or
the EpoR. Jak2 efficiently coimmunoprecipitated with
Btk (Fig. 2 A). Btk also coimmunoprecipitated with the
EpoR, but was not able to phosphorylate the EpoR in the
absence of Jak2 (Fig. 2 B). Because Epo-induced Btk
phosphorylation is independent of Src kinases, we tested
whether Jak2 or other kinases associated with the EpoR
complex are able to phosphorylate Btk. A kinase-dead
mutant of Btk (K430R) was expressed in COS cells to-
gether with Jak2, Lyn, or c-Kit. Jak2 and Lyn coimmuno-
precipitated with Btk and phosphorylated Btk on tyrosine
Figure 1. Epo and SCF induce Btk tyrosine phosphorylation. (A) Primary,
fetal liver–derived progenitors were factor deprived and restimulated with
Epo, SCF, or Epo/SCF as shown. Stimulation time is indicated in minutes.
Btk phosphorylation was analyzed using an anti-Y223 phospho-specific
antibody. Total Btk was stained to confirm equal loading. (B and C) wt
erythroid progenitor cells (2B6) were factor deprived in the absence or
presence of various concentrations of the PI3 kinase inhibitor LY294002
(B, LY) or the Src kinase inhibitor PP2 (C) as shown and restimulated
with Epo for 10 min. Btk immunoprecipitates were analyzed for phosphory-
lation using antiphosphotyrosine antibodies (PY99; p-Btk is the bottom
band) and restained for total Btk (B) or for phosphorylated proteins in total
cell lysates (TCLs) as a control (C). Size markers are indicated in kilodaltons. 
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(Fig. 2 C). To analyze whether, in reverse, Btk can phos-
phorylate Jak2, a kinase-dead mutant of Jak2 (K1114M)
was expressed in COS cells together with Lyn, Btk, Tec,
or c-Kit. Although Lyn efficiently phosphorylated Jak2,
Jak2 was not phosphorylated by Btk (Fig. 2 D). In contrast
to papers by others (31, 32), Tec was also not able to phos-
phorylate Jak2 in COS cells. In conclusion, Btk can coim-
munoprecipitate with the EpoR and Jak2, and Btk can
serve as a substrate for Jak2. This may explain the PP2-
resistant, Epo-induced Btk phosphorylation because PP2
did not affect Epo-induced Jak2 tyrosine phosphorylation
(Fig. 2 E). To test whether c-Kit directly associates with
and phosphorylates Btk, we coexpressed c-Kit with either
Btk or Btk (K430R). Although both 
 
wt
 
 and kinase-dead Btk
(K430R) coimmunoprecipitated with c-Kit, only 
 
wt
 
 Btk
was efficiently stained by antiphosphotyrosine antibody (Fig.
2 F). This suggests that c-Kit cannot directly phosphorylate
Btk and that SCF-induced phosphorylation of Btk uses addi-
tional kinases.
 
Btk
 
 
 
 Erythroid Progenitors Are Defective in Proliferation, But
Not in Differentiation.
 
Because we found Btk to be a sub-
strate of Epo/SCF signaling, we compared factor-depen-
dent survival, expansion, and differentiation of 
 
wt
 
 and Btk
 
 
 
progenitors. Fetal liver cells from E12.5 Btk
 
 
 
 and 
 
wt
 
 litter-
mates were cultured in medium supplemented with Epo,
SCF, and Dex. In both cultures, progenitors proliferated
with similar kinetics (Fig. 3 A). Because standard growth
factor concentrations (2 U/ml Epo and 100 ng/ml SCF)
exceed physiological concentrations to ensure long-term
expansion of progenitors at maximal proliferation rate, we
also examined expansion of 
 
wt
 
 and Btk
 
 
 
 cells at lower con-
centrations of Epo (0.5 U/ml) and SCF (25 ng/ml). Al-
though 
 
wt
 
 progenitors could be expanded for at least 10 d
at reduced growth factor concentrations, cultures of Btk
 
 
Figure 2. Btk coimmunoprecipitates with and is a
substrate of Jak2. (A–D and F) COS cells were trans-
fected with pSG5-based expression constructs encoding
the indicated proteins. Expression of all proteins was
verified in Western blots using specific antibodies (not
depicted). After 48 h, cells were stimulated with 5 U/ml
Epo (B) or 500 ng/ml SCF (C, lane 4; D and E, lane 4)
for 10 min, harvested, and lysed, and Btk (A and C),
EpoR (B), Jak2 (D), and c-Kit (F) were immunopre-
cipitated. (top panels) Immunoblots were stained with
antiphosphotyrosine antibodies (PY99). The blots were
restained with antibodies recognizing the immunopre-
cipitated proteins to check for equal loading. Arrows
indicate the position of the immunoprecipitated and
coimmunoprecipitating proteins. (E) wt erythroid pro-
genitors (2B6) were factor deprived in the absence or
presence of the Src kinase family inhibitor PP2 as indi-
cated and stimulated with Epo for 10 min. Epo-induced
Jak2 phosphorylation was assayed on immunoblots using
PY99 (top). (bottom) Blots were restained with anti-
Jak2 to confirm equal loading. (F) c-Kit immunopre-
cipitates were stained with antiphosphotyrosine antibodies
(PY99), and blots were restained with anti–c-Kit and
anti-Btk antibodies, whereas total cell lysates (TCLs)
were stained with anti–c-Kit and anti-Btk to check
expression levels. 
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progenitors became stationary at day 6 (Fig. 3 A). Analysis
of cell morphology and hemoglobin staining of Btk
 
 
 
 cul-
tures at day 6 showed an increase in mature erythrocytes at
the expense of erythroid progenitors as compared with 
 
wt
 
cells (Fig. 3 B). The same was evident by the much smaller
average cell size exhibited by Btk
 
 
 
 cells compared with 
 
wt
 
cells, determined using an electronic cell counter (unpub-
lished data). Concordantly, Btk
 
 
 
 cultures showed an in-
crease in hemoglobin levels compared with 
 
wt
 
 cultures
(Fig. 3 C, 3-fold at day 4; 11-fold at day 6). In conclusion,
Btk deficiency abrogates the expansion capacity of ery-
throid progenitors exposed to limiting concentrations of
Epo and SCF, favoring terminal differentiation at the ex-
pense of erythroid progenitor expansion.
To study Btk
 
 
 
 cells in detail, including biochemical as-
says, we established immortal cultures of p53-deficient
Btk
 
 
 
 and Btk
 
wt
 
 bone marrow–derived erythroid progeni-
tors (see Supplemental Material). At standard concentra-
tions of Epo and SCF, Btk
 
wt
 
 (2C6) and Btk
 
 
 
 (3E8) im-
mortal erythroid cultures could be similarly expanded and
retained a cell volume of 
 
 
 
800 fl. In contrast, decreased
concentrations of Epo (0.5 U/ml) and SCF (25 ng/ml)
caused rapid cell size reduction and growth arrest in the
Btk
 
 
 
 progenitors. Re-expression of Btk in Btk
 
 
 
 cells re-
stored the expansion capacity and blastlike cell size at re-
duced growth factor concentrations (Fig. 3 D).
The observation that progenitor expansion was impaired
in Btk
 
 
 
 cells, whereas progenitors underwent terminal dif-
ferentiation instead, suggests that Btk is not essential for dif-
ferentiation. However, Btk expression is maintained during
terminal differentiation, whereas EpoR expression decreases
during the later stages of differentiation (Fig. 3 E). To inves-
tigate whether Btk is required during Epo-induced terminal
erythroid differentiation, fetal liver–derived primary 
 
wt
 
 and
Btk
 
 
 
 progenitors were seeded in differentiation medium
containing varying concentrations of Epo (0.01–10 U/ml).
Although proliferation during differentiation showed an ex-
pected dependence on the Epo concentration, no differ-
ences between differentiating 
 
wt
 
 and Btk
 
 
 
 cultures were ob-
served with respect to proliferation kinetics, hemoglobin
content, or cell morphology (Fig. 3 F and not depicted).
 
EpoR Signaling Is Perturbed in Btk
 
 
 
 Erythroid Progenitors.
 
To unravel how Btk
 
 
 
 deficiency could impair Epo/SCF-
dependent progenitor expansion, we analyzed EpoR and
c-Kit signaling. Btk
 
wt
 
 (2C6) and Btk
 
 
 
 (3E8) immortalized
progenitors were factor deprived and restimulated with 5
Figure 3. Btk  erythroid progenitors
show enhanced differentiation at the expense
of renewal. (A) Btk  primary fetal liver pro-
genitors were seeded in medium containing
high (2 U/ml Epo and 100 ng/ml SCF) or
low (0.5 U/ml Epo and 25 ng/ml SCF)
concentrations of SCF and Epo, while
maintaining normal concentrations of Dex,
and cumulative cell numbers were deter-
mined. The different symbols represent two
independent experiments using wt and Btk 
erythroid progenitors as indicated. (B) Histo-
logical analysis of wt and Btk  cells described
in A at day 6 (A, arrow). The percentages of
erythroid cells at different stages of maturity
(as indicated) were scored for wt and Btk 
cultures and plotted in a pie chart. Percent-
age of immature cells: wt, 47%, and Btk ,
22%. Partially mature cells: wt, 21%, and
Btk , 28%. Mature cells: wt, 15%, and
Btk , 37%. Dead cells: wt, 17%, and Btk ,
12%. (C) Hemoglobin content (Hb/cell
volume in arbitrary units) of cells as described
in A was measured at days 4 and 6. (D) Btk 
bone marrow cell lines ectopically Btk-
reexpressing  (BtkRE) and Btk  cell lines
(Btk ) were treated as described in A. Open
symbols represent BtkRE, and closed symbols
represent Btk  cells cultured on low, high,
or no-growth factors (NF; see A). (E) Primary
fetal liver progenitors were seeded in differ-
entiation medium. Expression of Btk and
the EpoR during differentiation was checked
by Western blotting using Btk and EpoR
antibodies. Equal loading was examined using
an Actin antibody. (F) Cells were seeded in
differentiation conditions at 10, 0.1, and
0.01 Epo U/ml. Cumulative cell numbers
were determined. Symbols indicate the differ-
ent growth conditions as well as wt and
Btk  cultures.Btk Controls Erythropoietin Signaling and TRAIL Sensitivity 790
U/ml Epo. Epo-induced phosphorylation of PLC 1 was
completely abrogated in Btk  cells. Surprisingly, Epo-
induced phosphorylation of the EpoR, Jak2, and Stat5, was
also significantly reduced in the Btk  cells compared with wt
cells (Fig. 4 A). Epo-induced Stat5 phosphorylation was
similarly reduced in primary progenitors (Fig. 4 B and not
depicted). Re-expression of Btk in Btk  progenitors restored
the phosphorylation levels of the EpoR, Jak2, and Stat5 to
those in wt cells (Fig. 4 C). Although Btk was also phosphor-
ylated in response to SCF, SCF-induced phosphorylation of
c-Kit was not reduced in absence of Btk (Fig. 4 D). To rule
out that the impaired Epo-induced signal transduction in
Btk  cells was due to decreased cell surface expression of the
EpoR, expression of the EpoR and c-Kit was determined
by flow cytometry of nonpermeabilized cells. Surface ex-
pression of the EpoR and c-Kit was identical between wt
and Btk  erythroid progenitors, using the erythroid markers
TER119 and Integrin 4 as controls (Fig. 4 E).
Btk Controls Signaling Kinetics. To examine whether the
reduced response to Epo in Btk  cells could be caused by
altered signaling kinetics, the immortalized Btkwt (2C6),
Btk  (3E8), and Btk-reexpressing (RE) erythroid cells were
factor deprived and restimulated with Epo for 5, 10, 60, and
120 min; and Stat5 phosphorylation was assessed. Consis-
tently, Stat5 was rapidly phosphorylated in response to Epo
in wt and BtkRE cells, whereas phosphorylation in Btk 
cells was largely impaired. However, at late time points,
similar levels of Stat5 phosphorylation were observed in all
cell types (Fig. 5 A). Because Jak2 phosphorylates Stat5, Jak2
was immunoprecipitated from cell lysates generated at in-
creasing time intervals after Epo stimulation of wt (2C6) and
Btk  (3E8) cells. Maximal phosphorylation of Jak2 was ob-
served at 10–20 min after Epo stimulation in wt cells and
only at 40 min in Btk  cells (Fig. 5 B; the exposure of the
blots was adapted to show [de]activation kinetics for Btk 
and wt cells, requiring much longer exposure of the PY
blots in the Btk  panel). Also, phosphorylation of the
EpoR, though drastically reduced in Btk  cells, is less rap-
idly down-regulated (Fig. 5 C; requiring again different PY
exposures of Btk  and wt panels). Analysis of Epo-induced
Stat5 phosphorylation kinetics in primary bone marrow–
derived erythroid progenitors confirmed the results obtained
with the cell lines; Stat5 phosphorylation decreased after 20
min in wt cells, whereas it increased up to 90 min after Epo
stimulation in Btk  cells (Fig. 5 D).
Btk Regulates the Ligand Responsiveness of the EpoR. Be-
cause Btk controlled the efficiency of EpoR signaling in
time, it may also control the responsiveness to critical Epo
concentrations. Immortalized Btkwt (2C6), Btk  (3E8), and
BtkRE cells were factor deprived and restimulated with Epo
Figure 4. Btk  cells are perturbed in
Epo-induced signaling. (A–D) wt
(Btkwt), Btk  (Btk ), Btk-reexpressing
(BtkRE) bone marrow–derived erythroid
cell lines (A, C, and D), and primary wt
and Btk5  fetal liver progenitors (B) were
factor deprived and restimulated with 5
U/ml Epo or SCF as indicated for 10
min. Cells were lysed, and the immuno-
precipitated proteins as well as total cell
lysates (TCLs) were analyzed by Western
blotting. (top) Blots were stained with
the antiphosphotyrosine antibody PY99,
except for the TCLs (B), which were
stained in B with anti–phospho-
Tyr694/699 Stat5a/b. (bottom) The same
blots were restained with antibodies
recognizing the immunoprecipitated
protein as indicated or with anti–total
Stat5a/b for the TCLs. (E) Flow cyto-
metric analysis of cell surface expression
of c-Kit, TER119, Integrin 4 by specific
antibodies, and EpoR by biotinylated
Epo in wt (thick black line) and Btk 
(thin black line) erythroid progenitors.
Expression levels are also shown as histo-
grams depicting control stainings (dotted
line) and addition of excess Epo (gray
line) for EpoR detection. Mean fluo-
rescence values varied  10% for each
staining in three independent experiments,
indicating that wt and Btk  erythroid
progenitors express similar levels of the
respective cell surface markers.Schmidt et al. 791
at concentrations ranging from 0.5 to 10 U/ml. Stat5 phos-
phorylation became detectable in wt and Btk reexpressing
cells at 0.5 U/ml Epo, whereas similar levels were reached in
Btk  cells using 5 U/ml. With increasing levels of Epo, the
decrease in Epo-induced Stat5a/b phosphorylation in Btk 
cells became markedly less apparent (Fig. 5 E). Together, the
data show that Btk may have an important role in the regu-
lation of signaling efficiency both in time as well as in re-
sponse to suboptimal physiological concentrations of Epo.
Expansion of Btk  Erythroid Progenitors Is Inhibited by
TRAIL. Reduced sensitivity for Epo and hypersensitivity
for “death ligands” is associated in several pathological con-
ditions (9). Notably, loss of Btk has been shown to render B
cells more sensitive to Fas-induced apoptosis in response to
certain death signals (23, 41). To examine whether the re-
duced responsiveness to Epo in Btk  cells affects death
ligand–induced apoptosis in primary erythroid progenitors,
we expanded primary wt and Btk  erythroid progenitors
from fetal liver in presence of various death-inducing ligands.
INF  killed both wt and Btk  progenitors with identical ki-
netics, whereas the addition of 20 ng/ml FasL or 10 ng/ml
TNF  under optimal and suboptimal proliferation condi-
tions had no effect on wt or Btk  cells (unpublished data).
However, under optimal proliferation conditions, the addi-
tion of TRAIL (20 ng/ml) impaired the expansion of Btk 
progenitors, whereas wt control cells remained unaffected
(Fig. 6 A). Morphological analysis indicated the presence of
pycnotic cells (Fig. 6 B). On Western blots, Btkwt and Btk 
cells express similar levels of TRAILR1, indicating that in-
creased receptor expression is not the cause of the enhanced
TRAIL sensitivity (Fig. 6 C). Expression of TRAILR2 was
not observed in erythroid progenitors (Fig. 6 C).
It has been reported previously that Btk can interact
with Fas (23), whereas the Tec family member Bmx/Etk
undergoes ligand-independent interaction with TNF R2
(42). These interactions protected the cells from death
ligand–induced apoptosis and allowed TNF -induced cel-
lular migration and tube formation in epithelial cells.
Therefore, we tested whether Btk can interact with
TRAILR1 and whether this interaction is dependent on
either Epo or SCF. Progenitors expanded from wt fetal liv-
ers were factor deprived and subsequently restimulated
with Epo, SCF, and/or TRAIL. Btk immunoprecipitates
were analyzed for the presence of TRAILR1. Both SCF
and TRAIL, but not Epo, induced an interaction of Btk
and TRAILR1. In addition, costimulation of SCF and
TRAIL resulted in a significantly enhanced TRAILR1 re-
cruitment to Btk compared with SCF or TRAIL alone
(Fig. 6 D). This suggests that SCF may inhibit TRAIL-
induced apoptosis through enhancement of an interaction
between the TRAILR1 and Btk, which may cooperate
with reduced Epo responsiveness.
Figure 5. Btk  erythroid progenitors have a delayed Epo-induced
Jak2 and Stat5 phosphorylation. (A–E) wt (Btkwt), Btk  (Btk ), and Btk-
reexpressing (BtkRE) erythroid cell lines (A–C) or primary fetal liver
progenitors (D) were factor deprived and restimulated with 5 U/ml Epo
for the indicated times. Cells were lysed, and Jak2 (B) or the EpoR (C)
was immunoprecipitated. The immunoprecipitations as well as total cell
lysates (TCLs) were analyzed by Western blotting. (A and D) Blots were
stained with anti–phospho-Tyr694/699 Stat5a/b (top) and restained with
anti–total Stat5a/b to confirm equal loading (bottom). (B and C, top)
Blots were stained with antiphosphotyrosine PY99. (bottom) The same
blots were restained with anti-Jak2 or anti-EpoR to confirm equal loading.
PY-staining of these proteins in Btk  cells was much lower than in wt
cells. Therefore, Btk  panels were exposed much longer than wt panels
to enable proper comparison of kinetics of deactivation. (E) Erythroid
progenitors were restimulated with increasing concentrations of Epo for
10 min as indicated. (top) Blots stained with anti–phospho-Tyr694/699
Stat5a/b; (bottom) the same blots were restained with anti–total Stat5a/b.Btk Controls Erythropoietin Signaling and TRAIL Sensitivity 792
Discussion
Of all circulating blood cells, the maintenance of circu-
lating erythrocytes at constant, optimal numbers is most
important. Physiological levels of the major erythroid sur-
vival and expansion factor Epo are suboptimal ( 30 U/l in
mice), and only part of the progenitors survives in the bone
marrow to produce mature erythrocytes. In this paper, we
show that the cytoplasmic tyrosine kinase Btk is required
for an optimal response of erythroid progenitors to Epo,
and for SCF-mediated survival in presence of TRAIL.
Btk Is a Target of Jak2 and Controls the Efficacy of EpoR Sig-
naling. Stimulation of erythroid progenitors with Epo and
SCF induced phosphorylation of Btk on its autophosphory-
lation site Y223, indicating that catalytic activity of Btk is
enhanced after Epo and SCF stimulation. Interestingly, Jak2
and Lyn could phosphorylate Btk. Similarly, the Btk family
member Tec is mainly phosphorylated by Lyn, but can also
be phosphorylated by Jak1, Jak2, or Syk (31–33). Because
the Src kinase inhibitors PP1 and PP2 directly inhibit c-Kit
catalytic activity (reference 40 and unpublished data), we
did not investigate whether SCF-mediated Btk activation
requires Lyn. However, this is likely because c-Kit did not
efficiently phosphorylate kinase-dead Btk (Fig. 2, E and F),
whereas c-Kit is constitutively associated with Lyn in ery-
throid cells (36). Notably, Lyn phosphorylates Tec in re-
sponse to SCF, and the same mechanism may hold for Btk.
Btk was expected to be required for the phosphorylation
and activation of selected Epo-dependent signaling inter-
mediates like PLC 1, a known downstream target of Tec
kinases. However, the role of Btk in the control of Epo re-
sponsiveness was surprising. In the absence of Btk, Epo-
dependent phosphorylation of Jak2 and the EpoR required
increased levels of Epo or prolonged exposure to Epo. In
contrast, activation of the SCF receptor was not perturbed.
These data suggest that Btk may activate a signaling path-
way that acts as an enhancer of Jak2 activity. Such pathways
have not been described to date, but Btk does control sev-
eral signaling pathways that could be candidates for such a
function. First, Btk is required to activate PLC , whose
main effectors are classical protein kinase Cs (PKCs) of
which only PKC  is expressed in erythroid progenitors
(43). We have shown previously that inhibition of PKC 
does severely impair Epo-induced signal transduction simi-
lar to what we observe in Btk  cells (43). To test whether
the potential absence of a PLC -PKC  positive feedback
loop in Btk  cells could be responsible for their impaired
EpoR signaling, we examined whether direct activation of
PKC could restore a wt-like Epo responsiveness of EpoR
signaling in these cells. Both bryostatin and phorbol ester
enhanced Epo-induced phosphorylation of Jak2 and the
EpoR in Btk  cells, but the degree of enhancement was
not significantly stronger than in wt cells and did not fully
restore the Btk  signaling defect. Second, because Btk as-
sociates with Jak2, it may directly affect the Jak2-associated
protein complex. The Jak2-pseudokinase domain (Jak ho-
mology region 2) is important in the regulation of Jak2 ki-
nase activity (44). Its presence is required for inhibition of
Jak2 in the absence of cytokines and for cytokine inducibil-
ity of Jak2 activity and Stat5 phosphorylation. However,
the exact mechanism of this regulation has not been eluci-
dated. In conclusion, quantitative regulation of cytokine-
Figure 6. Btk  erythroid progenitors are no longer protected by SCF
from TRAIL-induced apoptosis. (A) wt and Btk  fetal liver cells were
seeded in medium containing Epo, SCF, and Dex in the presence and
absence of 20 ng/ml TRAIL, and cumulative cell numbers were deter-
mined. (B) At day 4, cytospins were prepared from cultures of wt and
Btk  cells in the presence of TRAIL (A, arrow) and stained with neutral
benzidine plus histological dyes. (C) Western blots from cell lysates of wt
and Btk  primary fetal liver erythroid progenitors and primary pro–B cells
were performed using anti-TRAILR1 and anti-TRAILR2 antibodies as
indicated. (D) wt primary fetal liver progenitors were factor deprived and
restimulated (for 10 min) with 5 U/ml Epo, 500 ng/ml SCF, and 200 ng/ml
TRAIL or combinations of factors as indicated. Btk was immunoprecipitated
from cell lysates and analyzed by Western blotting. Btk tyrosine phos-
phorylation was analyzed using an anti–phospho-Tyr223 Btk antibody
(top), whereas coimmunoprecipitation of TRAILR1 was checked with
anti-TRAILR1 (middle). Equal loading was confirmed by restaining the
same blot with total anti-Btk (bottom).Schmidt et al. 793
associated Jak2 may play a role in the Epo responsiveness of
erythroid progenitors and may be controlled by distinct
mechanisms dependent on either PKC or Btk.
Association of Btk with the TRAILR1 May Regulate
Sensitivity to TRAIL-induced Apoptosis. Regulation of the
apoptosis threshold is important during erythropoiesis and
several apoptosis inducers have been implicated in erythro-
poiesis such as TNF , FasL, or IFN  (9, 45–47). In ery-
throid progenitors, caspase activation in absence of EpoR
activation results in Gata-1 cleavage and apoptosis (48). The
cytoplasmic serine kinase Raf is required to prevent caspase
activation in immature cells (49). However, constitutive
inhibition of caspases blocks erythroid differentiation (49)
as caspase activity is required in late stages of erythroid dif-
ferentiation to cleave proteins involved in nuclear integrity
and chromatin condensation (50). We show that Btk can
associate with the TRAILR1 in response to SCF, which
may protect against TRAIL-induced apoptosis. Similarly,
Btk has been shown to inhibit Fas-induced apoptosis in
DT40 B cells, which was dependent on association of Btk
with Fas (23). We suggest that Btk-mediated protection
from apoptosis might involve a similar mechanism in both
cell types (i.e., interaction of the respective death receptor
with Btk). What remains puzzling is the observation that
both Epo and SCF induce phosphorylation of Btk, whereas
only SCF induces association of Btk with TRAILR1. This
could be explained by spatial constraints, which would im-
ply that the TRAILR1 and c-Kit are located in close prox-
imity. More likely, the association of Btk with either the
TRAILR1 or Fas requires an additional adaptor molecule
that is regulated in response to SCF, but not in response to
Epo. Such an adaptor molecule could also impose specific-
ity of Btk for distinct death receptors, such as Fas or
TRAILR1, in lymphoid or erythroid cells. In addition,
the intact kinase domain of Btk is required for its associa-
tion with Fas and probably also for its interaction with
TRAILR1 (23). Because wt and Btk  progenitors express
similar levels of TRAILR1, the increased apoptosis induc-
tion in Btk erythroblasts cannot be due to different expres-
sion levels of death receptor.
Btk Deficiency Impairs Renewal and Enhances Differentiation
at Limiting Cytokine Levels. Expansion of erythroid pro-
genitors in the presence of Epo, SCF, and Dex is abrogated
in Btk  progenitors at limiting concentrations of Epo and
SCF. Although the attenuated EpoR signaling and in-
creased TRAIL sensitivity of Btk  progenitors would have
predicted increased apoptosis at limiting cytokine concen-
trations, we observed enhanced differentiation at the ex-
pense of renewal. Our recent results indicate that the role of
EpoR signaling in early progenitors and maturing cells may
be distinct in function. In early erythroblasts, signaling path-
ways (triggered via intracellular p-Tyr docking sites in the
EpoR) contribute mostly to progenitor expansion because
erythroblasts from mice expressing a respective truncated
EpoR undergo normal differentiation, but are defective for
expansion of erythroblasts (unpublished data). These path-
ways include Epo-induced phosphorylation of Ron/Gab1
and activation of PI3 kinase and MAPK (unpublished data).
Furthermore, Epo-induced Stat5 activation is required for
survival in erythroid differentiation (up-regulating Bcl-XL),
whereas lack of Stat5 in expanding progenitors causes differ-
entiation at the expense of expansion in a Bcl-XL–indepen-
dent fashion (unpublished data). Moreover, because acti-
vated caspases contribute to execution of the late erythroid
differentiation program where apoptosis is prevented by up-
regulation of Bcl-XL (49, 51), impaired protection against
caspase activation in Btk  cells could contribute to differen-
tiation rather than to apoptosis. This suggests that the lack of
Btk may enhance differentiation using both Epo- and SCF-
activated signaling pathways.
Human X-linked agammaglobulinemia patients or Btk 
mice are not anemic and the mice do not present with in-
creased spleen size (a hallmark for stress erythropoiesis) as
do Stat5 /  mice (52). Importantly, we analyzed Btk 
mice for their response to hypoxia, which was similar to wt
littermates (see Supplemental Material). In vivo, Btk-defi-
cient cells showed a disadvantage over wt cells very late in
maturation (see Supplemental Material), but peripheral
erythrocyte numbers and cell size were similar in wt and
Btk  animals. Accordingly, we also found no indications
for increased Epo levels. Finally, numbers of early (BFU-E)
and late (CFU-E) progenitors were similar in fetal livers of
wt and Btk  animals (see Supplemental Material).
In conclusion, Btk appears to be involved in the control
of expansion, survival, and differentiation of erythroid pro-
genitors via two distinct mechanisms: (a) via the regulation
of Epo-induced signal transduction pathways with prolifer-
ation as the cellular readout and (b) via control of TRAIL-
induced apoptosis, which may involve SCF-dependent
association of Btk with TRAILR1. Interestingly, the com-
bination of a reduced Epo response and enhanced sensitiv-
ity to death ligands is a known pathological condition and
occurs, for example, in MDS (3, 8, 53). MDS constitutes a
very heterogeneous hematologic disease group that occurs
mainly in the elderly. Because a reduced response to Epo
and death ligand sensitivity are common, this condition
may be necessary but not sufficient to cause overt disease.
Rather, additional genetic aberrations may be required for
full development of MDS or even acute myeloid leukemia.
Therefore, it will be interesting to examine whether Btk 
mice are prone to develop leukemia upon further genetic
challenges (e.g., by retroviral insertion mutagenesis).
We want to thank Drs. T.B. van Dijk and I.P. Touw for many crit-
ical discussions regarding the work presented and Dr. J. Nimpf for
support during the early phase of the work. We thank Dr. K. Stangl,
G. Dingjan, S. Middendorp, and L. Felida for practical assistance, and
Dr. J. Borst for the Btkwt and Btk kinase dead cDNA constructs.
This work was supported by grants from the Dutch Cancer
Society (EUR 1999-2064), the European Union (HPRN-CT-
2000-00083), the START program (Y-163) of the FWF Austrian
Research Fund to W. Ellmeier, and fellowships from the Dutch
Academy of Arts and Sciences to M. von Lindern and from the
Fonds zur Förderung der Wissenschaftlichen Forschung Austria
(SFB006) to H. Beug.Btk Controls Erythropoietin Signaling and TRAIL Sensitivity 794
Submitted: 7 July 2003
Accepted: 30 December 2003
References
1. Wu, H., X. Liu, R. Jaenisch, and H.F. Lodish. 1995. Gener-
ation of committed erythroid BFU-E and CFU-E progeni-
tors does not require erythropoietin or the erythropoietin re-
ceptor. Cell. 83:59–67.
2. Flanagan, J.G., D.C. Chan, and P. Leder. 1991. Transmembrane
form of the kit ligand growth factor is determined by alternative
splicing and is missing in the Sld mutant. Cell. 64:1025–1035.
3. Shetty, V., S. Hussaini, L. Broady-Robinson, K. Allampal-
lam, S. Mundle, R. Borok, E. Broderick, L. Mazzoran, F.
Zorat, and A. Raza. 2000. Intramedullary apoptosis of he-
matopoietic cells in myelodysplastic syndrome patients can be
massive: apoptotic cells recovered from high-density fraction
of bone marrow aspirates. Blood. 96:1388–1392.
4. De Maria, R., A. Zeuner, A. Eramo, C. Domenichelli, D.
Bonci, F. Grignani, S.M. Srinivasula, E.S. Alnemri, U. Testa,
and C. Peschle. 1999. Negative regulation of erythropoiesis by
caspase-mediated cleavage of GATA-1. Nature. 401:489–493.
5. Dai, C.H., J.O. Price, T. Brunner, and S.B. Krantz. 1998.
Fas ligand is present in human erythroid colony-forming cells
and interacts with Fas induced by interferon gamma to pro-
duce erythroid cell apoptosis. Blood. 91:1235–1242.
6. Zamai, L., P. Secchiero, S. Pierpaoli, A. Bassini, S. Papa, E.S.
Alnemri, L. Guidotti, M. Vitale, and G. Zauli. 2000. TNF-
related apoptosis-inducing ligand (TRAIL) as a negative reg-
ulator of normal human erythropoiesis. Blood. 95:3716–3724.
7. Rusten, L.S., and S.E. Jacobsen. 1995. Tumor necrosis factor
(TNF)-alpha directly inhibits human erythropoiesis in vitro:
role of p55 and p75 TNF receptors. Blood. 85:989–996.
8. Hoefsloot, L.H., M.P. van Amelsvoort, L.C. Broeders, D.C.
van der Plas, K. van Lom, H. Hoogerbrugge, I.P. Touw, and
B. Lowenberg. 1997. Erythropoietin-induced activation of
STAT5 is impaired in the myelodysplastic syndrome. Blood.
89:1690–1700.
9. Claessens, Y.E., D. Bouscary, J.M. Dupont, F. Picard, J.
Melle, S. Gisselbrecht, C. Lacombe, F. Dreyfus, P. Mayeux,
and M. Fontenay-Roupie. 2002. In vitro proliferation and
differentiation of erythroid progenitors from patients with
myelodysplastic syndromes: evidence for Fas-dependent
apoptosis. Blood. 99:1594–1601.
10. von Lindern, M., W. Zauner, G. Mellitzer, P. Steinlein, G.
Fritsch, K. Huber, B. Lowenberg, and H. Beug. 1999. The
glucocorticoid receptor cooperates with the erythropoietin
receptor and c-Kit to enhance and sustain proliferation of
erythroid progenitors in vitro. Blood. 94:550–559.
11. Wessely, O., A. Bauer, C.T. Quang, E.M. Deiner, M. von
Lindern, G. Mellitzer, P. Steinlein, J. Ghysdael, and H. Beug.
1999. A novel way to induce erythroid progenitor self re-
newal: cooperation of c-Kit with the erythropoietin receptor.
Biol. Chem. 380:187–202.
12. Wessely, O., E.M. Deiner, H. Beug, and M. von Lindern.
1997. The glucocorticoid receptor is a key regulator of the
decision between self-renewal and differentiation in ery-
throid progenitors. EMBO J. 16:267–280.
13. Smith, M.A., E.L. Court, and J.G. Smith. 2001. Stem cell
factor: laboratory and clinical aspects. Blood Rev. 15:191–197.
14. Damen, J.E., and G. Krystal. 1996. Early events in erythro-
poietin-induced signaling. Exp. Hematol. 24:1455–1459.
15. Klingmuller, U., H. Wu, J.G. Hsiao, A. Toker, B.C. Duck-
worth, L.C. Cantley, and H.F. Lodish. 1997. Identification
of a novel pathway important for proliferation and differenti-
ation of primary erythroid progenitors. Proc. Natl. Acad. Sci.
USA. 94:3016–3021.
16. Taylor, M.L., and D.D. Metcalfe. 2000. Kit signal transduc-
tion. Hematol. Oncol. Clin. North Am. 14:517–535.
17. Wojchowski, D.M., R.C. Gregory, C.P. Miller, A.K. Pan-
dit, and T.J. Pircher. 1999. Signal transduction in the eryth-
ropoietin receptor system. Exp. Cell Res. 253:143–156.
18. Qiu, Y., and H.J. Kung. 2000. Signaling network of the Btk
family kinases. Oncogene. 19:5651–5661.
19. Yang, W.C., Y. Collette, J.A. Nunes, and D. Olive. 2000.
Tec kinases: a family with multiple roles in immunity. Immu-
nity. 12:373–382.
20. Khan, W.N., F.W. Alt, R.M. Gerstein, B.A. Malynn, I.
Larsson, G. Rathbun, L. Davidson, S. Muller, A.B. Kantor,
L.A. Herzenberg, et al. 1995. Defective B cell development
and function in Btk-deficient mice. Immunity. 3:283–299.
21. Conley, M.E., J. Rohrer, and Y. Minegishi. 2000. X-linked
agammaglobulinemia. Clin. Rev. Allergy Immunol. 19:183–204.
22. Hendriks, R.W., M.F. de Bruijn, A. Maas, G.M. Dingjan, A.
Karis, and F. Grosveld. 1996. Inactivation of Btk by insertion
of lacZ reveals defects in B cell development only past the
pre-B cell stage. EMBO J. 15:4862–4872.
23. Vassilev, A., Z. Ozer, C. Navara, S. Mahajan, and F.M.
Uckun. 1999. Bruton’s tyrosine kinase as an inhibitor of the
Fas/CD95 death-inducing signaling complex. J. Biol. Chem.
274:1646–1656.
24. Uckun, F.M., K.G. Waddick, S. Mahajan, X. Jun, M.
Takata, J. Bolen, and T. Kurosaki. 1996. BTK as a mediator
of radiation-induced apoptosis in DT-40 lymphoma B cells.
Science. 273:1096–1100.
25. Li, Z., M.I. Wahl, A. Eguinoa, L.R. Stephens, P.T. Hawk-
ins, and O.N. Witte. 1997. Phosphatidylinositol 3-kinase-
gamma activates Bruton’s tyrosine kinase in concert with Src
family kinases. Proc. Natl. Acad. Sci. USA. 94:13820–13825.
26. Suzuki, H., S. Matsuda, Y. Terauchi, M. Fujiwara, T.
Ohteki, T. Asano, T.W. Behrens, T. Kouro, K. Takatsu, T.
Kadowaki, and S. Koyasu. 2003. PI3K and Btk differentially
regulate B cell antigen receptor-mediated signal transduction.
Nat. Immunol. 4:280–286.
27. Saito, K., A.M. Scharenberg, and J.P. Kinet. 2001. Interac-
tion between the Btk PH domain and phosphatidylinositol-
3,4,5-trisphosphate directly regulates Btk. J. Biol. Chem. 276:
16201–16206.
28. Hansson, H., M.P. Okoh, C.I. Smith, M. Vihinen, and T.
Hard. 2001. Intermolecular interactions between the SH3
domain and the proline-rich TH region of Bruton’s tyrosine
kinase. FEBS Lett. 489:67–70.
29. Laederach, A., K.W. Cradic, K.N. Brazin, J. Zamoon, D.B.
Fulton, X.Y. Huang, and A.H. Andreotti. 2002. Competing
modes of self-association in the regulatory domains of Bru-
ton’s tyrosine kinase: intramolecular contact versus asymmet-
ric homodimerization. Protein Sci. 11:36–45.
30. Pursglove, S.E., T.D. Mulhern, J.P. Mackay, M.G. Hinds,
and G.W. Booker. 2002. The solution structure and in-
tramolecular associations of the Tec kinase SRC homology 3
domain. J. Biol. Chem. 277:755–762.
31. Takahashi-Tezuka, M., M. Hibi, Y. Fujitani, T. Fukada, T.
Yamaguchi, and T. Hirano. 1997. Tec tyrosine kinase links
the cytokine receptors to PI-3 kinase probably through JAK.
Oncogene. 14:2273–2282.
32. Yamashita, Y., S. Watanabe, A. Miyazato, K. Ohya, U.Schmidt et al. 795
Ikeda, K. Shimada, N. Komatsu, K. Hatake, Y. Miura, K.
Ozawa, and H. Mano. 1998. Tec and Jak2 kinases cooperate
to mediate cytokine-driven activation of c-fos transcription.
Blood. 91:1496–1507.
33. Baba, Y., S. Hashimoto, M. Matsushita, D. Watanabe, T.
Kishimoto, T. Kurosaki, and S. Tsukada. 2001. BLNK medi-
ates Syk-dependent Btk activation. Proc. Natl. Acad. Sci.
USA. 98:2582–2586.
34. Robinson, D., H.C. Chen, D. Li, J.T. Yustein, F. He, W.C.
Lin, M.J. Hayman, and H.J. Kung. 1998. Tyrosine kinase ex-
pression profiles of chicken erythro-progenitor cells and on-
cogene-transformed erythroblasts. J. Biomed. Sci. 5:93–100.
35. Whyatt, D., F. Lindeboom, A. Karis, R. Ferreira, E. Milot,
R. Hendriks, M. de Bruijn, A. Langeveld, J. Gribnau, F.
Grosveld, and S. Philipsen. 2000. An intrinsic but cell-non-
autonomous defect in GATA-1-overexpressing mouse ery-
throid cells. Nature. 406:519–524.
36. van Dijk, T.B., E. van Den Akker, M.P. Amelsvoort, H.
Mano, B. Lowenberg, and M. von Lindern. 2000. Stem cell
factor induces phosphatidylinositol 3 -kinase-dependent
Lyn/Tec/Dok-1 complex formation in hematopoietic cells.
Blood. 96:3406–3413.
37. von Lindern, M., E.M. Deiner, H. Dolznig, M. Parren-Van
Amelsvoort, M.J. Hayman, E.W. Mullner, and H. Beug.
2001. Leukemic transformation of normal murine erythroid
progenitors: v- and c-ErbB act through signaling pathways
activated by the EpoR and c-Kit in stress erythropoiesis. On-
cogene. 20:3651–3664.
38. Kowenz, E., A. Leutz, G. Doderlein, T. Graf, and H. Beug.
1987. ts-oncogene-transformed erythroleukemic cells: a
novel test system for purifying and characterizing avian ery-
throid growth factors. Hamatol. Bluttransfus. 31:199–209.
39. Beug, H., S. Palmieri, C. Freudenstein, H. Zentgraf, and T.
Graf. 1982. Hormone-dependent terminal differentiation in
vitro of chicken erythroleukemia cells transformed by ts mu-
tants of avian erythroblastosis virus. Cell. 28:907–919.
40. Tatton, L., G.M. Morley, R. Chopra, and A. Khwaja. 2003.
The Src-selective kinase inhibitor PP1 also inhibits Kit and
Bcr-Abl tyrosine kinases. J. Biol. Chem. 278:4847–4853.
41. Tumang, J.R., R.S. Negm, L.A. Solt, T.J. Schneider, T.P.
Colarusso, W.D. Hastings, R.T. Woodland, and T.L. Roth-
stein. 2002. BCR engagement induces Fas resistance in pri-
mary B cells in the absence of functional Bruton’s tyrosine
kinase. J. Immunol. 168:2712–2719.
42. Pan, S., P. An, R. Zhang, X. He, G. Yin, and W. Min. 2002.
Etk/Bmx as a tumor necrosis factor receptor type 2-specific
kinase: role in endothelial cell migration and angiogenesis.
Mol. Cell. Biol. 22:7512–7523.
43. von Lindern, M., M. Parren-van Amelsvoort, T. van Dijk, E.
Deiner, E. van den Akker, S. van Emst-de Vries, P. Willems,
H. Beug, and B. Lowenberg. 2000. Protein kinase C alpha
controls erythropoietin receptor signaling. J. Biol. Chem. 275:
34719–34727.
44. Saharinen, P., and O. Silvennoinen. 2002. The pseudokinase
domain is required for suppression of basal activity of Jak2
and Jak3 tyrosine kinases and for cytokine-inducible activa-
tion of signal transduction. J. Biol. Chem. 277:47954–47963.
45. Silvestris, F., P. Cafforio, M. Tucci, and F. Dammacco. 2002.
Negative regulation of erythroblast maturation by Fas-L( )/
TRAIL( ) highly malignant plasma cells: a major pathoge-
netic mechanism of anemia in multiple myeloma. Blood. 99:
1305–1313.
46. Tsushima, H., Y. Imaizumi, D. Imanishi, K. Fuchigami, and
M. Tomonaga. 1999. Fas antigen (CD95) in pure erythroid
cell line AS-E2 is induced by interferon-gamma and tumor
necrosis factor-alpha and potentiates apoptotic death. Exp.
Hematol. 27:433–440.
47. Chung, I.J., C. Dai, and S.B. Krantz. 2003. Stem cell factor
increases the expression of FLIP that inhibits IFNgamma-
induced apoptosis in human erythroid progenitor cells. Blood.
101:1324–1328.
48. De Maria, R., U. Testa, L. Luchetti, A. Zeuner, G. Stassi, E.
Pelosi, R. Riccioni, N. Felli, P. Samoggia, and C. Peschle.
1999. Apoptotic role of Fas/Fas ligand system in the regula-
tion of erythropoiesis. Blood. 93:796–803.
49. Kolbus, A., S. Pilat, Z. Husak, E.M. Deiner, G. Stengl, H.
Beug, and M. Baccarini. 2002. Raf-1 antagonizes erythroid
differentiation by restraining caspase activation. J. Exp. Med.
196:1347–1353.
50. Zermati, Y., C. Garrido, S. Amsellem, S. Fishelson, D. Bous-
cary, F. Valensi, B. Varet, E. Solary, and O. Hermine. 2001.
Caspase activation is required for terminal erythroid differen-
tiation. J. Exp. Med. 193:247–254.
51. Dolznig, H., B. Habermann, K. Stangl, E.M. Deiner, R.
Moriggl, H. Beug, and E.W. Müllner. 2002. Apoptosis protec-
tion by the Epo target Bcl-XL allows factor-independent differ-
entiation of primary erythroblasts. Curr. Biol. 12:1076–1085.
52. Socolovsky, M., H. Nam, M.D. Fleming, V.H. Haase, C.
Brugnara, and H.F. Lodish. 2001. Ineffective erythropoiesis
in Stat5a( / )5b( / ) mice due to decreased survival of
early erythroblasts. Blood. 98:3261–3273.
53. Gersuk, G.M., C. Beckham, M.R. Loken, P. Kiener, J.E.
Anderson, A. Farrand, A.B. Troutt, J.A. Ledbetter, and H.J.
Deeg. 1998. A role for tumour necrosis factor-alpha, Fas and
Fas-Ligand in marrow failure associated with myelodysplastic
syndrome. Br. J. Haematol. 103:176–188.